


Dual therapy: MET+CANA vs. MET+SU reduction in body weight* over 104 weeks (LOCF)¹⁻³



Canagliflozin is not licensed for weight loss.

*Pre-specified secondary endpoint. **glimepiride titrated up to a maximum of 8mg once-daily.²

The maximum licensed dose of glimepiride is 6mg.³

LS: Least-squares, CI: Confidence interval, SE: Standard error, LOCF: Last observation carried forward.

Reference: 1. Cefalu WT et al. Poster presented at the 73rd Scientific Sessions of the ADA. 2. Cefalu WT et al. The Lancet 2013, 382 (9896); 941-950. 3. AMARYL Summary of Product Characteristics, dated 17/10/2013 (last accessed August 2014).

This slide deck has been developed by Janssen and is intended for a UK healthcare professional audience only.

PHGB/MEDed/1113/0016(1)a Date of preparation: August 2014